3/120
0.1 / 5 stars
All 120 Win/Lose results shown below
ALLR Roast Me summary
Allarity Therapeutics, Inc. (ALLR). Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
- 2026-Q2: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Lose; EPS growth Lose.
Trailing 1 year (4 quarters): 3 wins, 9 lossesLast fetched: 25 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
WinALLR / S&P 18.35% / 15.20% |
LoseALLR / S&P ALLR unavailable / 15.00% |
LoseALLR / S&P ALLR unavailable / 50.40% |
| 2026-Q11/3 |
WinALLR / S&P 0.93% / -4.33% |
LoseALLR / S&P ALLR unavailable / 11.30% |
LoseALLR / S&P ALLR unavailable / 27.70% |
| 2025-Q40/3 |
LoseALLR / S&P -31.65% / 2.65% |
LoseALLR / S&P ALLR unavailable / 9.00% |
LoseALLR / S&P ALLR unavailable / 13.40% |
| 2025-Q31/3 |
WinALLR / S&P 56.44% / 8.12% |
LoseALLR / S&P ALLR unavailable / 4.61% |
LoseALLR / S&P ALLR unavailable / 13.45% |
| 2025-Q20/3 |
LoseALLR / S&P 7.79% / 10.94% |
LoseALLR / S&P ALLR unavailable / 4.83% |
LoseALLR / S&P ALLR unavailable / 10.63% |
| 2025-Q10/3 |
LoseALLR / S&P -19.91% / -4.27% |
LoseALLR / S&P ALLR unavailable / 4.98% |
LoseALLR / S&P ALLR unavailable / 10.57% |
| 2024-Q40/3 |
LoseALLR / S&P -44.55% / 2.41% |
LoseALLR / S&P ALLR unavailable / 5.25% |
LoseALLR / S&P ALLR unavailable / 6.15% |
| 2024-Q30/3 |
LoseALLR / S&P -66.98% / 5.89% |
LoseALLR / S&P ALLR unavailable / 5.89% |
LoseALLR / S&P ALLR unavailable / 6.11% |
| 2024-Q20/3 |
LoseALLR / S&P -96.46% / 4.28% |
LoseALLR / S&P ALLR unavailable / 5.38% |
LoseALLR / S&P ALLR unavailable / 5.12% |
| 2024-Q10/3 |
LoseALLR / S&P -45.37% / 10.56% |
LoseALLR / S&P ALLR unavailable / 5.71% |
LoseALLR / S&P ALLR unavailable / 5.59% |
| 2023-Q40/3 |
LoseALLR / S&P -26.24% / 11.69% |
LoseALLR / S&P ALLR unavailable / 6.81% |
LoseALLR / S&P ALLR unavailable / 7.78% |
| 2023-Q30/3 |
LoseALLR / S&P -88.68% / -3.27% |
LoseALLR / S&P ALLR unavailable / 7.52% |
LoseALLR / S&P ALLR unavailable / -5.03% |
| 2023-Q20/3 |
LoseALLR / S&P -90.18% / 8.74% |
LoseALLR / S&P ALLR unavailable / 9.50% |
LoseALLR / S&P ALLR unavailable / -8.57% |
| 2023-Q10/3 |
LoseALLR / S&P -83.67% / 7.50% |
LoseALLR / S&P ALLR unavailable / 10.77% |
LoseALLR / S&P ALLR unavailable / -15.69% |
| 2022-Q40/3 |
LoseALLR / S&P -73.27% / 7.56% |
LoseALLR / S&P ALLR unavailable / 11.88% |
LoseALLR / S&P ALLR unavailable / -17.99% |
| 2022-Q30/3 |
LoseALLR / S&P -16.67% / -4.88% |
LoseALLR / S&P ALLR unavailable / 13.47% |
LoseALLR / S&P ALLR unavailable / -1.41% |
| 2022-Q20/3 |
LoseALLR / S&P -35.29% / -16.10% |
LoseALLR / S&P ALLR unavailable / 13.71% |
LoseALLR / S&P ALLR unavailable / 11.04% |
| 2022-Q10/3 |
LoseALLR / S&P -80.34% / -4.60% |
LoseALLR / S&P ALLR unavailable / 15.97% |
LoseALLR / S&P ALLR unavailable / 42.23% |
| 2021-Q40/3 |
LoseALLR / S&P ALLR unavailable / 11.03% |
LoseALLR / S&P ALLR unavailable / 15.00% |
LoseALLR / S&P ALLR unavailable / 96.40% |
| 2021-Q30/3 |
LoseALLR / S&P ALLR unavailable / 0.58% |
LoseALLR / S&P ALLR unavailable / 10.77% |
LoseALLR / S&P ALLR unavailable / 69.42% |
| 2021-Q20/3 |
LoseALLR / S&P ALLR unavailable / 8.55% |
LoseALLR / S&P ALLR unavailable / 6.58% |
LoseALLR / S&P ALLR unavailable / 51.81% |
| 2021-Q10/3 |
LoseALLR / S&P ALLR unavailable / 6.17% |
LoseALLR / S&P ALLR unavailable / -1.06% |
LoseALLR / S&P ALLR unavailable / 7.39% |
| 2020-Q40/3 |
LoseALLR / S&P ALLR unavailable / 12.15% |
LoseALLR / S&P ALLR unavailable / -3.72% |
LoseALLR / S&P ALLR unavailable / -33.42% |
| 2020-Q30/3 |
LoseALLR / S&P ALLR unavailable / 8.93% |
LoseALLR / S&P ALLR unavailable / -2.04% |
LoseALLR / S&P ALLR unavailable / -27.10% |
| 2020-Q20/3 |
LoseALLR / S&P ALLR unavailable / 20.54% |
LoseALLR / S&P ALLR unavailable / -0.46% |
LoseALLR / S&P ALLR unavailable / -27.11% |
| 2020-Q10/3 |
LoseALLR / S&P ALLR unavailable / -19.60% |
LoseALLR / S&P ALLR unavailable / 3.47% |
LoseALLR / S&P ALLR unavailable / -14.75% |
| 2019-Q40/3 |
LoseALLR / S&P ALLR unavailable / 9.07% |
LoseALLR / S&P ALLR unavailable / 5.36% |
LoseALLR / S&P ALLR unavailable / 2.99% |
| 2019-Q30/3 |
LoseALLR / S&P ALLR unavailable / 1.70% |
LoseALLR / S&P ALLR unavailable / 5.02% |
LoseALLR / S&P ALLR unavailable / 0.21% |
| 2019-Q20/3 |
LoseALLR / S&P ALLR unavailable / 4.30% |
LoseALLR / S&P ALLR unavailable / 6.64% |
LoseALLR / S&P ALLR unavailable / 8.65% |
| 2019-Q10/3 |
LoseALLR / S&P ALLR unavailable / 13.65% |
LoseALLR / S&P ALLR unavailable / 8.12% |
LoseALLR / S&P ALLR unavailable / 14.29% |
| 2018-Q40/3 |
LoseALLR / S&P ALLR unavailable / -13.52% |
LoseALLR / S&P ALLR unavailable / 9.05% |
LoseALLR / S&P ALLR unavailable / 18.23% |
| 2018-Q30/3 |
LoseALLR / S&P ALLR unavailable / 7.71% |
LoseALLR / S&P ALLR unavailable / 10.21% |
LoseALLR / S&P ALLR unavailable / 19.06% |
| 2018-Q20/3 |
LoseALLR / S&P ALLR unavailable / 3.43% |
LoseALLR / S&P ALLR unavailable / 9.03% |
LoseALLR / S&P ALLR unavailable / 14.46% |
| 2018-Q10/3 |
LoseALLR / S&P ALLR unavailable / -0.76% |
LoseALLR / S&P ALLR unavailable / 7.68% |
LoseALLR / S&P ALLR unavailable / 12.46% |
| 2017-Q40/3 |
LoseALLR / S&P ALLR unavailable / 6.64% |
LoseALLR / S&P ALLR unavailable / 7.03% |
LoseALLR / S&P ALLR unavailable / 13.82% |
| 2017-Q30/3 |
LoseALLR / S&P ALLR unavailable / 4.48% |
LoseALLR / S&P ALLR unavailable / 5.68% |
LoseALLR / S&P ALLR unavailable / 17.57% |
| 2017-Q20/3 |
LoseALLR / S&P ALLR unavailable / 3.09% |
LoseALLR / S&P ALLR unavailable / 4.83% |
LoseALLR / S&P ALLR unavailable / 17.74% |
| 2017-Q10/3 |
LoseALLR / S&P ALLR unavailable / 6.07% |
LoseALLR / S&P ALLR unavailable / 3.67% |
LoseALLR / S&P ALLR unavailable / 13.32% |
| 2016-Q40/3 |
LoseALLR / S&P ALLR unavailable / 3.82% |
LoseALLR / S&P ALLR unavailable / 2.09% |
LoseALLR / S&P ALLR unavailable / 7.05% |
| 2016-Q30/3 |
LoseALLR / S&P ALLR unavailable / 3.85% |
LoseALLR / S&P ALLR unavailable / 0.20% |
LoseALLR / S&P ALLR unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-28
| Metric | ALLR total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -7.75% | 20.78% |
| Annualized return | -7.75% | 20.78% |
5Y · 2021-12-21 to 2026-08-28
| Metric | ALLR total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -100.00% | 83.14% |
| Annualized return | -95.62% | 12.86% |
10Y · 2021-12-21 to 2026-08-28
| Metric | ALLR total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -100.00% | 319.30% |
| Annualized return | -79.07% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-25.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B |